亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B

医学 遗传增强 基因 计算生物学 遗传学 生物
作者
Steven W. Pipe,Frank W.G. Leebeek,Michael Recht,Nigel S. Key,Giancarlo Castaman,Wolfgang Miesbach,Susan Lattimore,Kathelijne Peerlinck,Paul Van der Valk,Michiel Coppens,Peter Kampmann,Karina Meijer,Niamh M O'Connell,John Pasi,Daniel P. Hart,Rashid Saeed Kazmi,Jan Astermark,Cedric R.J.R. Hermans,Robert Klamroth,Richard S. Lemons
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:388 (8): 706-718 被引量:393
标识
DOI:10.1056/nejmoa2211644
摘要

BACKGROUND: Moderate-to-severe hemophilia B is treated with lifelong, continuous coagulation factor IX replacement to prevent bleeding. Gene therapy for hemophilia B aims to establish sustained factor IX activity, thereby protecting against bleeding without burdensome factor IX replacement. METHODS: genome copies per kilogram of body weight) to 54 men with hemophilia B (factor IX activity ≤2% of the normal value) regardless of preexisting AAV5 neutralizing antibodies. The primary end point was the annualized bleeding rate, evaluated in a noninferiority analysis comparing the rate during months 7 through 18 after etranacogene dezaparvovec treatment with the rate during the lead-in period. Noninferiority of etranacogene dezaparvovec was defined as an upper limit of the two-sided 95% Wald confidence interval of the annualized bleeding rate ratio that was less than the noninferiority margin of 1.8. Superiority, additional efficacy measures, and safety were also assessed. RESULTS: The annualized bleeding rate decreased from 4.19 (95% confidence interval [CI], 3.22 to 5.45) during the lead-in period to 1.51 (95% CI, 0.81 to 2.82) during months 7 through 18 after treatment, for a rate ratio of 0.36 (95% Wald CI, 0.20 to 0.64; P<0.001), demonstrating noninferiority and superiority of etranacogene dezaparvovec as compared with factor IX prophylaxis. Factor IX activity had increased from baseline by a least-squares mean of 36.2 percentage points (95% CI, 31.4 to 41.0) at 6 months and 34.3 percentage points (95% CI, 29.5 to 39.1) at 18 months after treatment, and usage of factor IX concentrate decreased by a mean of 248,825 IU per year per participant in the post-treatment period (P<0.001 for all three comparisons). Benefits and safety were observed in participants with predose AAV5 neutralizing antibody titers of less than 700. No treatment-related serious adverse events occurred. CONCLUSIONS: Etranacogene dezaparvovec gene therapy was superior to prophylactic factor IX with respect to the annualized bleeding rate, and it had a favorable safety profile. (Funded by uniQure and CSL Behring; HOPE-B ClinicalTrials.gov number, NCT03569891.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
SUNny发布了新的文献求助10
9秒前
11秒前
明理的芝完成签到 ,获得积分10
11秒前
正直的晓槐完成签到,获得积分10
22秒前
灵巧小夏完成签到,获得积分10
25秒前
国色不染尘完成签到,获得积分10
37秒前
44秒前
夏鹿发布了新的文献求助10
48秒前
mc发布了新的文献求助10
49秒前
夏鹿完成签到,获得积分20
54秒前
56秒前
腼腆的如南完成签到,获得积分10
58秒前
36hours发布了新的文献求助200
1分钟前
1分钟前
1分钟前
null的应助被科研通管家采纳,获得10
1分钟前
null的应助被科研通管家采纳,获得30
1分钟前
null的应助被科研通管家采纳,获得47
1分钟前
36hours发布了新的文献求助50
1分钟前
拼搏的小凝完成签到,获得积分10
1分钟前
mc完成签到,获得积分10
1分钟前
gtgyh完成签到 ,获得积分10
1分钟前
1分钟前
SUNny发布了新的文献求助10
1分钟前
36hours发布了新的文献求助100
1分钟前
Lisa完成签到 ,获得积分10
1分钟前
monthli完成签到,获得积分10
1分钟前
迷路飞凤完成签到,获得积分10
1分钟前
沉默岩完成签到,获得积分10
2分钟前
哭泣振家完成签到,获得积分10
2分钟前
2分钟前
多情柚子完成签到,获得积分10
2分钟前
2分钟前
36hours发布了新的文献求助200
2分钟前
冷静的冥王星完成签到,获得积分10
2分钟前
阿切尔代发布了新的文献求助10
2分钟前
阿切尔代完成签到,获得积分10
3分钟前
机灵寄柔完成签到,获得积分10
3分钟前
孤独难胜完成签到,获得积分10
4分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8166228
求助须知:如何正确求助?哪些是违规求助? 9559448
关于积分的说明 21750389
捐赠科研通 7757056
什么是DOI,文献DOI怎么找? 3429141
关于科研通互助平台的介绍 2553436
邀请新用户注册赠送积分活动 2473781